Literature DB >> 16231011

Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels.

Richard G Webster1, Keith L Brain, Richard H Wilson, Jean L Grem, Angela Vincent.   

Abstract

Oxaliplatin, an effective cytotoxic treatment in combination with 5-fluorouracil for colorectal cancer, is associated with sensory, motor and autonomic neurotoxicity. Motor symptoms include hyperexcitability while autonomic effects include urinary retention, but the cause of these side-effects is unknown. We examined the effects on motor nerve function in the mouse hemidiaphragm and on the autonomic system in the vas deferens. In the mouse diaphragm, oxaliplatin (0.5 mM) induced multiple endplate potentials (EPPs) following a single stimulus, and was associated with an increase in spontaneous miniature EPP frequency. In the vas deferens, spontaneous excitatory junction potential frequency was increased after 30 min exposure to oxaliplatin; no changes in resting Ca(2+) concentration in nerve terminal varicosities were observed, and recovery after stimuli trains was unaffected. In both tissues, an oxaliplatin-induced increase in spontaneous activity was prevented by the voltage-gated Na(+) channel blocker tetrodotoxin (TTX). Carbamazepine (0.3 mM) also prevented multiple EPPs and the increase in spontaneous activity in both tissues. In diaphragm, beta-pompilidotoxin (100 microM), which slows Na(+) channel inactivation, induced multiple EPPs similar to oxaliplatin's effect. By contrast, blockers of K(+) channels (4-aminopyridine and apamin) did not replicate oxaliplatin-induced hyperexcitability in the diaphragm. The prevention of hyperexcitability by TTX blockade implies that oxaliplatin acts on nerve conduction rather than by effecting repolarisation. The similarity between beta-pompilidotoxin and oxaliplatin suggests that alteration of voltage-gated Na(+) channel kinetics is likely to underlie the acute neurotoxic actions of oxaliplatin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16231011      PMCID: PMC1751225          DOI: 10.1038/sj.bjp.0706407

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  45 in total

1.  ATP-dependent Ca-uptake by rat vas deferens smooth muscle microsomes: properties of oxalate stimulated and oxalate-independent Ca-uptake.

Authors:  A K Grover; C Y Kwan
Journal:  Arch Int Pharmacodyn Ther       Date:  1984-01

2.  Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.

Authors:  Christian Lersch; Renate Schmelz; Florian Eckel; Johannes Erdmann; Martina Mayr; Ewert Schulte-Frohlinde; Stefan Quasthoff; Julian Grosskreutz; Helmuth Adelsberger
Journal:  Clin Colorectal Cancer       Date:  2002-05       Impact factor: 4.481

3.  Expanding the phenotype of potassium channelopathy: severe neuromyotonia and skeletal deformities without prominent Episodic Ataxia.

Authors:  M Kinali; H Jungbluth; L H Eunson; C A Sewry; A Y Manzur; E Mercuri; M G Hanna; F Muntoni
Journal:  Neuromuscul Disord       Date:  2004-10       Impact factor: 4.296

Review 4.  Neuromyotonia.

Authors:  J Newsom-Davis
Journal:  Rev Neurol (Paris)       Date:  2004-05       Impact factor: 2.607

5.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

6.  Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction.

Authors:  R H Thomsen; D F Wilson
Journal:  J Pharmacol Exp Ther       Date:  1983-10       Impact factor: 4.030

7.  Inhibition of Na(+) current by imipramine and related compounds: different binding kinetics as an inactivation stabilizer and as an open channel blocker.

Authors:  Ya-Chin Yang; Chung-Chin Kuo
Journal:  Mol Pharmacol       Date:  2002-11       Impact factor: 4.436

8.  Functional characterization and cold sensitivity of T1313A, a new mutation of the skeletal muscle sodium channel causing paramyotonia congenita in humans.

Authors:  Magali Bouhours; Damien Sternberg; Claire-Sophie Davoine; Xavier Ferrer; Jean Claude Willer; Bertrand Fontaine; Nacira Tabti
Journal:  J Physiol       Date:  2003-11-14       Impact factor: 5.182

9.  Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.

Authors:  Laurence Gamelin; Michele Boisdron-Celle; Remy Delva; Véronique Guérin-Meyer; Norbert Ifrah; Alain Morel; Erick Gamelin
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

10.  Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.

Authors:  T J Lehky; G D Leonard; R H Wilson; J L Grem; M K Floeter
Journal:  Muscle Nerve       Date:  2004-03       Impact factor: 3.217

View more
  41 in total

Review 1.  Neurologic toxicities of cancer therapies.

Authors:  Robert Cavaliere; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

2.  The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical, and histopathological studies.

Authors:  Mansour S Al Moundhri; Suhail Al-Salam; Ahmed Al Mahrouqee; S Beegam; Badreldin H Ali
Journal:  J Med Toxicol       Date:  2013-03

3.  A reversible coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance.

Authors:  Michele Basso; Alessandra Cassano; Anna Modoni; Daniele Spada; Nunziatina Trigila; Michela Quirino; Giovanni Schinzari; Carlo Barone
Journal:  Eur J Clin Pharmacol       Date:  2008-03-19       Impact factor: 2.953

Review 4.  Emerging trends in understanding chemotherapy-induced peripheral neuropathy.

Authors:  Jérémy Ferrier; Vanessa Pereira; Jérome Busserolles; Nicolas Authier; David Balayssac
Journal:  Curr Pain Headache Rep       Date:  2013-10

Review 5.  Mitotoxicity in distal symmetrical sensory peripheral neuropathies.

Authors:  Gary J Bennett; Timothy Doyle; Daniela Salvemini
Journal:  Nat Rev Neurol       Date:  2014-05-20       Impact factor: 42.937

Review 6.  [Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options].

Authors:  T Kowalski; C Maier; A Reinacher-Schick; U Schlegel
Journal:  Schmerz       Date:  2008-02       Impact factor: 1.107

7.  Transient bilateral abducens neuropathy with post-tetanic facilitation and acute hypokalemia associated with oxaliplatin: a case report.

Authors:  Min-Han Tan; Wen Yee Chay; Jia Hui Ng; Bin Tean Teh; Lita Chew
Journal:  J Med Case Rep       Date:  2010-02-02

8.  Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.

Authors:  Andrew Hill; Peter Bergin; Fritha Hanning; Paul Thompson; Michael Findlay; Dragan Damianovich; Mark J McKeage
Journal:  BMC Cancer       Date:  2010-08-23       Impact factor: 4.430

9.  Novel pathologic findings associated with urinary retention in a mouse model of mucopolysaccharidosis type IIIB.

Authors:  Sylvia I Gografe; Paul R Sanberg; Wilfredo Chamizo; Hector Monforte; Svitlana Garbuzova-Davis
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

10.  Oxaliplatin neurotoxicity--no general ion channel surface-charge effect.

Authors:  Amir Broomand; Elin Jerremalm; Jeffrey Yachnin; Hans Ehrsson; Fredrik Elinder
Journal:  J Negat Results Biomed       Date:  2009-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.